Kangmei Pharmaceutical Co.

Kangmei Pharmaceutical Co.

Kangmei Pharmaceutical Co. was founded in the 1990s by the Ma family, building a large-scale traditional Chinese medicine business based in Puning, Guangdong. The company went public on the Shanghai Stock Exchange in 2001 and became one of China's largest producers of herbal products. In 2021, following a major accounting fraud investigation, the firm was delisted and underwent state-led restructuring, with the family retaining significant private holdings. The family office now invests across multiple asset classes, including healthcare services, real estate, and infrastructure, with a growing interest in renewable energy. Known geographic footprints include China, Hong Kong, and the United States, with additional offices in Europe. The office operates through a network of holding companies and family trusts, with direct investments and co-investments in operating businesses. The office maintains a global presence with offices in Seattle, San Rafael, Padova, Stockholm, and Luxembourg, indicating a diversified investment strategy. No recent operational events from the last 24 months were publicly captured. The office is known for long-term holdings rather than frequent deal-making. A structural differentiator is the office's origin in a publicly traded company that underwent a high-profile fraud and restructuring, requiring complex governance transitions. The family office functions as a vehicle to manage the remaining private wealth separate from the state-restructured entity, with a focus on international diversification. Succession and control dynamics remain opaque, typical of many Chinese family offices.